February 16th, 2007
Acute lymphoblastic leukemia is the most common cancer in children. In such cases when the WNT pathway becomes altered, administration of medication like quercetine or Decitabine® normalizes this cell control pathway.
With this group of medicines, chemotherapy results are enhanced and survival rates improved.
Such were the findings of Spanish Scientists as described in the journal Blood […]
By Gloria Gamat -- 0 comments
January 12th, 2007
A new mechanism by which arsenite (a form of arsenic) acts in the treatment of a rare cancer called acute promyelocytic leukemia (APL) have been identified by researchers at Dartmouth Medical School (DMS).
APL is caused by the swapping of chromosomes 15 and 17, which forms a fusion protein. This fusion protein prevents certain blood cells […]
By Gloria Gamat -- 0 comments
December 21st, 2006
In a phase II trial led by a University of North Carolina at Chapel Hill School of Medicine researcher found that a newly formulated chemotherapy drug Doxil (doxorubicin delivered via liposomes, or microscopic fat bubbles) combined with standard therapy Velcade slows the progression of multiple myeloma better than Velcade alone.
Multiple myeloma is an advanced cancer […]
By Gloria Gamat -- 0 comments
October 17th, 2006
St. Jude Children’s Research Hospital clinicians successfully demonstrated an improved technique for blood stem cell transplantations in children that shows promise for those most likely to fail standard treatment for leukemia.
The St. Jude technique: allowing blood stem cells to come from parents or unmatched adult siblings thereby avoiding the aggressive, toxic treatments that usually must […]
By Gloria Gamat -- 0 comments
October 16th, 2006
Derived from Genta Incorporated (Nasdaq: GNTA)’s DNA/RNA Medicines Program, G4460 is the company’s new anticancer drug that uses antisense technology to target an oncogene known as c-myb that regulates key functions in cancer cells.
G4460 targets an oncogene product known as c-myb, which is a protein that directly binds to cellular DNA. C-myb is believed to regulate […]
By Gloria Gamat -- 0 comments
September 23rd, 2006
Cytogen Corporation (Nasdaq: CYTO) has recently published a new data related to its QUADRAMET® (samarium Sm-153 lexidronam injection) product, in an article by Vilmarie Rodriguez, M.D. (a Pediatric Oncologist at The Mayo Clinic in Rochester, Minnesota) entitled “Marrow irradiation with high-dose 153 Samarium-EDTMP followed by chemotherapy and hematopoietic stem cell infusion for acute myelogenous leukemia” […]
By Gloria Gamat -- 0 comments
June 20th, 2006
Gleevec is the standard treatment for chronic myeloid leukemia. When patients failed to respond to this treatment, an experimental drug called Dasatinib, under development by Bristol-Myers Squibb was able to reverse the signs and symptoms of the disorder.
These findings from the phase I clinical trial that evaluated the safety and toxicity at different dose levels […]
By Gloria Gamat -- 0 comments
Recent Comments